Nurix Therapeutics, Inc. ( NRIX ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Nurix Therapeutics (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics ( NRIX ) : Here's What You Should Know
The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 143.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Immunome ( IMNM ) Soars 6.0%: Is Further Upside Left in the Stock?
Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Beyond Air, Inc. ( XAIR ) Reports Q4 Loss, Misses Revenue Estimates
Beyond Air (XAIR) delivered earnings and revenue surprises of 35.71% and 17.12%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, June 13, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at ...
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg ( NX-5948 ) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia ( CLL ) and Waldenström Macroglobulinemia ( WM )
Complete response achieved in CLL. overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM ...
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg ( NX-5948 ) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia ( CLL ) and Waldenström Macroglobulinemia ( WM ) - Nurix Therapeutics ( NASDAQ:NRIX )
Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg ( NX-5948 ) Being Presented at the 30th European Hematology Association Congress ( EHA2025 ) - Nurix Therapeutics ( NASDAQ:NRIX )
SAN FRANCISCO, June 06, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc.
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg ( NX-5948 ) Being Presented at the 30th European Hematology Association Congress ( EHA2025 )
SAN FRANCISCO, June 06, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that the company will host a webcast ...
Nurix Therapeutics ( NRIX ) Moves 14.2% Higher: Will This Strength Last?
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout - Nurix Therapeutics ( NASDAQ:NRIX ) , Blueprint Medicines ( NASDAQ:BPMC ) , Sanofi ( NASDAQ:SNY )
Ayvakit earned $150 million in Q1 2025, up over 60% year over year. Sanofi's $9.5 billion deal includes Ayvakit, elenestinib, and BLU-808. Get access to the leaderboards pointing to tomorrow's biggest stock movers. Sanofi SA SNY on Monday agreed to acquire Blueprint Medicines Corporation BPMC.
Sanofi Exercises License Extension Option to Nurix's STAT6 Program
Sanofi Licenses Nurix's STAT6 program ...
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference - Nurix Therapeutics ( NASDAQ:NRIX )
SAN FRANCISCO, May 28, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. NRIX, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur T.
Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma
SAN FRANCISCO, May 14, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that data from the Company's ongoing ...
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour ...
Cathie Wood Buys More NVIDIA And AMD Stock As Chinese Tech Giants Stockpile Chips Amid Looming US Export Curbs - Advanced Micro Devices ( NASDAQ:AMD ) , Adaptive Biotechnologies ( NASDAQ:ADPT )
On Wednesday, Cathie Wood-led Ark Invest increased its exposure to NVIDIA Corp NVDA and Advanced Micro Devices Inc AMD. These trades come amid ongoing challenges in the semiconductor industry, particularly with U.S. sanctions affecting chip sales to China.
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, April 11, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at ...
Nurix Therapeutics, Inc. ( NRIX ) Reports Q1 Loss, Tops Revenue Estimates
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of 6.94% and 26.41%, respectively, for the quarter ended February 2025. Do the numbers hold clues to what lies ahead for the stock?
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
Nurix stock gains as SNY expands its partnership, licensing a research program targeting a previously untreatable transcription factor for autoimmune diseases.
Nurix Therapeutics, Inc. ( NRIX ) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases - Nurix Therapeutics ( NASDAQ:NRIX )
The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this previously undruggable target
Cue Biopharma, Inc. ( CUE ) Reports Q4 Loss, Misses Revenue Estimates
Cue Biopharma (CUE) delivered earnings and revenue surprises of 18.75% and 5.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Spero Therapeutics, Inc. ( SPRO ) Reports Q4 Loss, Tops Revenue Estimates
Spero Therapeutics (SPRO) delivered earnings and revenue surprises of -8.57% and 21.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research ( AACR ) 2025 Annual Meeting
SAN FRANCISCO, March 25, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that company scientists will present ...
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Nurix Therapeutics ( NASDAQ:NRIX )
SAN FRANCISCO, March 14, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc.
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, March 14, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at ...
Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors
Dr. Baynes has been a member of Nurix's Medical Advisory Board since 2023 Dr. Baynes has been a member of Nurix's Medical Advisory Board since ...
ProQR ( PRQR ) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) delivered earnings and revenue surprises of -42.86% and 51.53%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks ( ZYME ) Soars 5.4%: Is Further Upside Left in the Stock?
Zymeworks (ZYME) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Xilio Therapeutics, Inc. ( XLO ) Reports Q4 Loss, Lags Revenue Estimates
Xilio Therapeutics (XLO) delivered earnings and revenue surprises of 9.09% and 23.72%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Feb. 14, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at ...
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Nurix Therapeutics ( NASDAQ:NRIX )
SAN FRANCISCO, Feb. 04, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc.
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
SAN FRANCISCO, Feb. 04, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at ...
Nurix Therapeutics, Inc. ( NRIX ) Reports Q4 Loss, Lags Revenue Estimates
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -11.94% and 22.55%, respectively, for the quarter ended November 2024. Do the numbers hold clues to what lies ahead for the stock?
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting
MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- Oryzon Genomics, S.A. ( ISIN Code: ES0167733015, ORY ) , a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces significant changes to its Board ...
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting
MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- Oryzon Genomics, S.A. ( ISIN Code: ES0167733015, ORY ) , a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces significant changes to its Board ...
Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer - Nurix Therapeutics ( NASDAQ:NRIX )
SAN FRANCISCO, Jan. 22, 2025 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. NRIX, a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of John Northcott as chief ...
Strength Seen in SpringWorks Therapeutics ( SWTX ) : Can Its 6.0% Jump Turn into More Strength?
SpringWorks Therapeutics (SWTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia
Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom's Macroglobulinemia Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom's Macroglobulinemia ...
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia - Nurix Therapeutics ( NASDAQ:NRIX )
SAN FRANCISCO, Dec. 19, 2024 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. NRIX, a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the U.S.
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting
Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments ...
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting - Nurix Therapeutics ( NASDAQ:NRIX )
Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology ( ASH ) Annual Meeting
SAN FRANCISCO, Dec. 02, 2024 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a ...
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - Nurix Therapeutics ( NASDAQ:NRIX )
SAN FRANCISCO, Nov. 25, 2024 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. NRIX, a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T.
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
SAN FRANCISCO, Nov. 25, 2024 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX ) , a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T.
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia - Nurix Therapeutics ( NASDAQ:NRIX )
The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation Pivotal trials of NX-5948 are planned to initiate in 2025 SAN FRANCISCO, Nov. 20, 2024 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc.
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation ...
As Tesla Rides Trump Rally, Cathie Wood Sells $15.4M Worth Of Stock - Tesla ( NASDAQ:TSLA ) , ARK Innovation ETF ( ARCA:ARKK )
On Tuesday, Cathie Wood-led Ark Invest made a notable move by offloading a significant number of shares in Tesla Inc TSLA. This decision comes amidst a surge in Tesla's stock, fueled by reports of the incoming administration's plans to ease restrictions on self-driving vehicles.
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseases Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase ...
Cathie Wood's Latest Shake-up: Dumps Palantir And Jack Dorsey's Block Along With Tesla, Buys Amazon And Meta - Amazon.com ( NASDAQ:AMZN )
On Monday, Cathie Wood-led Ark Invest made significant trades, with the most notable being the trades in Coinbase Global Inc COIN, Meta Platforms Inc META, Palantir Technologies Inc PLTR, Block Inc SQ, Tesla Inc TSLA and Amazon.com, Inc AMZN.
